While some DDR-targeting agents, mainly of the Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) class, have been approved for management of ovarian cancers, relatively little was known about the utility of other DDR-targeting agents in an OCCC-specific context. This evidence concerns the gene PARP1 and ovarian carcinoma.